Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Fenelon

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Neurology|May 28, 2004
Vascular parkinsonismIgor Sibon, Gilles Fenelon, Niall P Quinn, et al.
Expert Review of Clinical Pharmacology|November 26, 2011
Can nicotine be used medicinally in Parkinson's disease?Claire Thiriez, Gabriel Villafane, Frédérique Grapin, et al.
Brain Stimulation|July 17, 2010
Paroxysmal positive symptoms caused by hardware malfunctioning in deep brain stimulationDaniel Ciampi de Andrade, Jean-Marc Gurruchaga, Bechir Jarraya, et al.
Lancet (London, England)|January 14, 2014
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trialStéphane Palfi, Jean Marc Gurruchaga, G Scott Ralph, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Neurology|May 28, 2004
Vascular parkinsonismIgor Sibon, Gilles Fenelon, Niall P Quinn, et al.
Expert Review of Clinical Pharmacology|November 26, 2011
Can nicotine be used medicinally in Parkinson's disease?Claire Thiriez, Gabriel Villafane, Frédérique Grapin, et al.
Brain Stimulation|July 17, 2010
Paroxysmal positive symptoms caused by hardware malfunctioning in deep brain stimulationDaniel Ciampi de Andrade, Jean-Marc Gurruchaga, Bechir Jarraya, et al.
Lancet (London, England)|January 14, 2014
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trialStéphane Palfi, Jean Marc Gurruchaga, G Scott Ralph, et al.
Pageof 1